Bellerophon Therapeutics Inc.
https://bellerophon.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bellerophon Therapeutics Inc.
Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO
Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.
Pipeline Watch: Phase III Progress With Burosumab, Duvelisib And Galcanezumab
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Starts With DCC-2618, Tislelizumab And Tabelecleucel
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Deals Shaping The Medical Industry, October 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.
Company Information
- Industry
- Pharmaceuticals